Application of punicalagin as aromatic hydrocarbon regulator in preparation of medicine for preventing and treating sepsis

By significantly upregulating the expression of aromatic hydrocarbon receptors by using amphilidine, the side effects and non-specific problems of aromatic hydrocarbon receptor regulators in the prior art are solved, and the survival of sepsis mice is achieved safely and effectively improves the survival of sepsis mice in the treatment of sepsis rate effect.

CN118924779APending Publication Date: 2024-11-12CHINESE PEOPLES LIBERATION ARMY ARMY SPECIAL MEDICAL CENTER
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411249706.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing aromatic hydrocarbon receptor agonists or inhibitors have strong toxic side effects and non-specific biological effects in the prevention and treatment of sepsis, which is difficult to apply to clinical treatment, and lacks the regulation of selective upregulation of aromatic hydrocarbon receptor protein expression. agent.

Method used

Using pomegranin as an aromatic hydrocarbon receptor regulator can significantly upregulate aromatic hydrocarbon receptor expression and mRNA expression levels in macrophages alone or in combination with lipopolysaccharides to enhance the expression of aromatic hydrocarbon receptors, thereby alleviating sepsis.

Benefits of technology

Ampolin significantly improves the survival rate of septic mice and does not affect the survival rate of AhR knockout mice, proving that it is a safe and effective aromatic hydrocarbon receptor regulator with potential clinical therapeutic value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924779A_ABST
    Figure CN118924779A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and discloses application of punicalagin as an aromatic hydrocarbon receptor modulator in preparation of drugs for preventing and treating sepsis. The punicalagin is determined as a novel aromatic hydrocarbon receptor (AhR) regulator, can enhance the gene and protein expression effect of the aromatic hydrocarbon receptor (AhR), and does not affect the functions of AhR nuclear transport and gene transcription. The invention finds that punicalagin can obviously improve the survival rate of mice with sepsis by adjusting an aromatic hydrocarbon receptor (AhR), and discloses a new application of punicalagin in the aspect of preventing and treating sepsis. It is further shown that punicalagin can be used as a potential clinical treatment medicine and has a wide application prospect in the aspect of preparing the medicine for preventing and treating sepsis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and particularly relates to an application of punicalagin as an aromatic hydrocarbon regulator in the preparation of a drug for preventing and treating sepsis. Background Art

[0002] Sepsis is a life-threatening organ dysfunction caused by the body's dysregulated response to infection. It is a serious disease and one of the main causes of death in critically ill patients. The pathogenesis of sepsis is complex and involves pathological changes in multiple tissues and organs throughout the body. Although some progress has been made in sepsis research, the incidence and mortality of sepsis remain high, and the existing preventive and therapeutic drugs and measures are insufficient. There is an urgent need to find new drugs to prevent and treat sepsis and septic organ damage.

[0003] The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor composed of 805 amino acids and belongs to the basic helix-loop-helix transcription factor family. Previously, AhR was believed to mainly mediate the metabolism of environmental toxicants. Recently, it has been found that AhR is involved in the regulation of infection, inflammation and immune response, suggesting that AhR is a potential regulatory target for the prevention and treatment of sepsis. At present, AhR agonists or inhibitors mainly play a role by promoting or inhibiting the genomic pathway of AhR nuclear entry. Most of them have strong toxic side effects and non-specific biological effects, and are difficult to apply to clinical treatment. AhR can also play a beneficial role in inflammation and immune regulation through non-genomic pathways, which mainly depends on the expression and regulation of AhR protein. AhR modulators are compounds that have the ability to regulate the expression of AhR protein, but the AhR modulators currently developed and applied are obviously insufficient. Therefore, finding modulators that selectively upregulate AhR protein expression is a more precise intervention strategy for sepsis.

[0004] Punicalagin (PUN) is the main active ingredient in pomegranate peel polyphenols and is a Chinese medicine monomer isolated from it. PUN has been found to play an important role in anti-oxidation, anti-tumor, anti-bacterial, anti-viral, and anti-inflammatory effects. However, there are no reports on its ability to prevent and treat sepsis and septic organ damage. Summary of the invention

[0005] The present invention aims to solve one of the technical problems in the related art at least to a certain extent. To this end, the main purpose of the present invention is to provide the use of punicalagin as an aromatic hydrocarbon receptor modulator in the preparation of a drug for preventing and treating sepsis.

[0006] The objective of the present invention is achieved through the following technical solutions:

[0007] Application of punicalagin in the preparation of drugs for preventing and treating sepsis.

[0008] The structural formula of punicalagin is:

[0009]

[0010] Wherein the punicalagin is capable of regulating the expression of the aryl hydrocarbon receptor;

[0011] Furthermore, the punicalagin can upregulate the expression of aryl hydrocarbon receptor;

[0012] The research concept of the present invention is as follows:

[0013] The affinity of punicalagin (PUN) to AhR is significantly lower than that of other ligands. PUN cannot act on the activation domain of AhR and has no activity to activate AhR. PUN does not induce AhR nuclear translocation, nor does it affect the DNA binding activity between the nuclear protein and DRE on the AhR promoter, and does not activate the transcription of AhR downstream genes. In in vivo and in vitro experiments, it was found that punicalagin alone or in combination with lipopolysaccharide could upregulate the expression level of AhR protein and mRNA in mouse peritoneal macrophages, and the combined treatment was more effective. Punicalagin can significantly enhance the expression of AhR in a time- and dose-dependent manner. In human THP-1 cells, it was also proved that PUN has the effect of upregulating AhR expression. It is thus determined that punicalagin, as an aryl hydrocarbon receptor modulator, has the effect of enhancing the expression of aryl hydrocarbon receptor. Punicalagin can improve the survival rate of wild-type mice in the sepsis model caused by LPS and CLP, but does not affect the survival rate of AhR knockout mice, indicating that punicalagin can significantly improve the survival rate of septic mice through AhR. In summary, punicalagin, as an aryl hydrocarbon receptor modulator, upregulates the expression of aryl hydrocarbon receptors in macrophages, thereby alleviating sepsis and achieving the purpose of treating sepsis.

[0014] In certain specific embodiments, the sepsis includes early sepsis, severe sepsis and septic shock.

[0015] In certain specific embodiments, the drug also includes a pharmaceutically acceptable excipient, and the pharmaceutically acceptable excipient further includes one or more of a diluent, a wetting agent, a binder, a disintegrant, a lubricant, a color and flavor regulator, a solvent, a solubilizer, a cosolvent, an emulsifier, an antioxidant, a metal complexing agent, an inert gas, a preservative, a local analgesic, a pH regulator, an isotonic regulator, and an isotonic regulator.

[0016] The effective dosage of the drug is 6.25-25 mg / kg.

[0017] In certain specific embodiments, the dosage form of the drug includes one of injection, oral solution, pill, powder, paste, tablet, granule, powder or capsule.

[0018] In certain specific embodiments, the administration route of the drug includes one of intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, oral administration, sublingual administration, nasal administration or transdermal administration.

[0019] The drug of the present invention can also be used in combination with other drugs for treating sepsis. The combined use of multiple drugs can greatly increase the success rate of treatment.

[0020] Compared with the prior art, the present invention has at least the following advantages:

[0021] 1) The present invention identifies punicalagin as a novel aryl hydrocarbon receptor (AhR) modulator that can enhance the expression of aryl hydrocarbon receptor (AhR) gene and protein without affecting the nuclear transport and gene transcription functions of AhR;

[0022] 2) The drug of the present invention adopts punicalagin, a safe, effective and cheap natural Chinese medicine monomer drug, as the main active ingredient, and has the characteristics of wide source of raw materials, simple extraction process, low drug toxicity, etc.; the present invention finds that punicalagin can significantly improve the survival rate of septic mice by regulating the aryl hydrocarbon receptor (AhR), revealing a new use of punicalagin in preventing and treating sepsis; further shows that punicalagin can be used as a potential clinical therapeutic drug and has broad application prospects in the preparation of drugs for preventing and treating sepsis. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the specific embodiments of the present invention, the drawings required for use in the specific embodiments or the description of the prior art will be briefly introduced below.

[0024] Figure 1 The figure shows the results of Western blotting to detect the effect of punicalagin on AhR protein expression in mouse peritoneal macrophages;

[0025] Figure 2 This is the result of detecting the effect of punicalagin on the mean fluorescence intensity of AhR protein in mouse peritoneal macrophages by cell immunofluorescence method;

[0026] Figure 3 This is the result of flow cytometry detection of the effect of punicalagin on the percentage of AhR-positive macrophages in peritoneal macrophages of LPS-stimulated mice;

[0027] Figure 4 This is the result of detecting the effect of punicalagin on the expression level of AhR mRNA in mouse peritoneal macrophages by fluorescence quantitative PCR;

[0028] Figure 5 The results of Western blotting to detect the effect of punicalagin on AhR protein expression in THP-1 cells;

[0029] Figure 6 This is the result graph showing that punicalagin improves the survival rate of wild-type mice in the LPS-induced sepsis model, but does not affect the survival rate of AhR knockout mice;

[0030] Figure 7 This is the result graph showing that punicalagin improves the survival rate of wild-type mice in the CLP-induced sepsis model, but does not affect the survival rate of AhR knockout mice. DETAILED DESCRIPTION

[0031] In order to make the purpose, technical solution and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments, but it should not be understood as limiting the scope of protection of the present invention. Any equivalent changes in form made based on the concept of the present invention should be regarded as the scope of the present invention.

[0032] The present invention provides a general and / or specific description of the materials and test methods used in the experiment. The test methods or test methods involved are all conventional methods unless otherwise specified; the reagents or instruments used are all conventional products available on the market, prepared or used in a conventional manner, unless the manufacturer is specified.

[0033] Example 1: Punicalagin promotes AhR expression in macrophages

[0034] 1. Experimental materials:

[0035] 1.1 Experimental animals and cells: SPF-grade C57BL / 6J mice, 6-8 weeks old, 18-22 grams, provided by the Experimental Animal Center of Army Medical University; THP-1 cells were provided by Wuhan Pronocell Life Science Co., Ltd.

[0036] 1.2 Experimental reagents: Punicalagin was purchased from Chengdu Mansite Biotechnology Co., Ltd. (CAS No.: 65995-63-3, purity>98%); LPS was purchased from Sigma; AhR WB antibody was purchased from Enzo life sciences; AhR immunofluorescence antibody was purchased from GeneTex; FITC-F4 / 80 anti-mouse antibody and BV605-CD11b anti-mouse antibody were purchased from Biolegend; PE-AhR antibody or PE anti-mouse isotype antibody was purchased from Bio-Osen; PCR primers were synthesized at Qingke Biotechnology Co., Ltd.; RPMI-1640 culture medium and fetal bovine serum were purchased from Gbico, USA; Western and IP lysis buffer and horseradish peroxidase secondary antibody were purchased from Shanghai Biyuntian Biotechnology Co., Ltd.; red blood cell lysis buffer was purchased from Tianjin Haoyang Huake Biotechnology Co., Ltd.; TGX Stain-Free gel preparation kit was purchased from Bio-Rad, USA; high-purity total RNA rapid extraction kit was purchased from Beijing Biotech Biotechnology Co., Ltd., PrimeScript RT reagent Kit ExTaqTMII kits were purchased from TAKARA, Japan.

[0037] 1.3. Experimental instruments: ChemiDoc MP imager, C1000 Thermal Cycler quantitative PCR instrument, CFX96 Touch fluorescence quantitative PCR detection system were purchased from Bio-Rad, USA; laser scanning confocal microscope was purchased from Olympus, USA; Cytek Aurora full spectrum flow cytometer was purchased from Cytek, USA.

[0038] 2. Experimental methods:

[0039] 2.1 Cell extraction and drug treatment

[0040] Mice were intraperitoneally injected with 1 ml of thiol broth 3 days ago, and then the mice were killed by dislocation of the neck to extract the enriched peritoneal macrophages. After cutting the abdominal wall, 5 ml of pre-cooled saline and 1 ml of air were injected, and the abdomen was massaged to allow the fluid to flow fully in the peritoneal cavity. The mouse peritoneal lavage fluid was aspirated, centrifuged at 300g for 5 minutes, and the cell pellet was added with red blood cell lysis buffer for 5 minutes at room temperature. After the same amount of culture medium was terminated, the cell pellet was centrifuged and resuspended, and then inoculated into a cell culture plate. After the plate was attached to the wall for 2 hours, the supernatant was discarded. The adherent cells were peritoneal macrophages. After drug treatment, different concentrations (12.5μM, 25μM and 50μM) of PUN were pretreated for 1 hour in advance, and 10μg / ml LPS was added for different time periods (4h, 8h and 12h). Western blotting, cell immunofluorescence and flow cytometry were used to detect the protein expression of AhR, and real-time fluorescence quantitative RT-PCR was used to detect the mRNA expression of AhR.

[0041] 2.1.1. Protein sample preparation and Western blot detection of AhR protein expression

[0042] The cells were washed twice with PBS and the total cell protein was extracted using Western and IP cell lysis buffers and PMSF. After protein quantification by the BCA method, protein samples were prepared and SDS-PAGE gels were prepared using TGX Stain-Free Fast Cast Acrylamide Kits. After conventional Western blot electrophoresis, the gel was immersed in 1× electrotransfer buffer and the Stain Free Gel program was performed using the ChemiDoc MP imager from Bio-rad. The proteins on the gel were activated by UV Transillumination and then imaged to obtain the total protein image of each lane. Total protein quantitative loading control was used as the internal reference for protein loading amount. Total protein quantification is more accurate and convenient than housekeeping genes. The membrane was transferred using Bio-rad's Trans-Blot Turbo universal protein transfer system, blocked with 5% skim milk powder at room temperature for 1 hour, incubated with primary antibody AhR (BML-SA210) at 4°C overnight, and incubated with secondary antibody horseradish peroxidase-labeled goat anti-rabbit secondary antibody solution after washing the next day. ECL development was performed, and the gel imaging system was exposed. ImageJ was used to perform quantitative analysis of protein bands.

[0043] 2.1.2. Detection of AhR protein expression by cell immunofluorescence

[0044] The cells on the confocal dish were fixed with 4% paraformaldehyde for 30 min, permeabilized with 0.5% Triton X-100 for 10 min, and stained with QuickBlock TM Block with blocking buffer for 60 minutes. Incubate cells with AhR (GTX22770, GeneTex) antibody at 4°C overnight, and then incubate with Alexa Fluor 647-conjugated secondary antibody at room temperature for 1 hour. Add DAPI staining solution for 10 minutes. Image using laser scanning confocal microscopy. After DAPI staining of cell nuclei, images were collected and analyzed using a laser scanning confocal microscope (Olympus).

[0045] 2.1.3 Detection of AhR protein expression by flow cytometry

[0046] Twelve hours after intraperitoneal injection of punicalagin solution, mouse peritoneal macrophages were isolated and prepared into single cell suspensions. The cells were surface stained with a predetermined optimal concentration of flow fluorescence antibody (FITC-F4 / 80 anti-mouse antibody, BV605-CD11b anti-mouse antibody) and incubated on ice for 15 minutes in the dark. The cells were fixed with a fixation / permeabilization solution for 2 hours. The cells were stained with a flow fluorescence antibody (PE-AhR anti-mouse antibody). After incubation in the dark for 30 minutes, washing and centrifugation, the cells were resuspended in PBS and analyzed using a Cytek Aurora full-spectrum flow cytometer.

[0047] 2.1.4. Fluorescence quantitative PCR detection of mRNA expression and transcriptome sequencing

[0048] The cells were washed twice with PBS, and 1 ml of Trizol was added to collect the total RNA attached to the PM. RNA was extracted according to the steps of the RNA extraction kit, and the concentration and purity of RNA were tested. According to the TaKaRa RR047A kit, 0.5-1 μg RNA was reverse transcribed into cDNA according to the TaKaRa RR820A kit for qPCR quantitative analysis. The AhR primer sequences were Forward primer: CAAATCCTTCTAAGCGACACAG; Reverse primer: TGACGCTGAGCCTAAGAACA , the β-actin primer sequence is Forward primer: AGCCATGTACGTAGCCATCC ; Reverse primer: CTCTCAGCTGTGGTGGTGAA. Amplification conditions: 95℃3min, 95℃10s, 60℃30s, 40 cycles. Gene expression levels were calculated based on the obtained Ct values.

[0049] 3. Experimental results:

[0050] The results are as follows Figure 1 , Figure 2 , Figure 3 , Figure 4 and Figure 5 As shown, from Figure 1 It can be seen that punicalagin alone or in combination with lipopolysaccharide can upregulate the expression level of AhR protein in mouse peritoneal macrophages; Figure 2 It can be seen that punicalagin alone or in combination with lipopolysaccharide can increase the mean fluorescence intensity of AhR protein in mouse peritoneal macrophages; Figure 3 It can be seen that punicalagin can increase the percentage of AhR positive macrophages in LPS-stimulated mouse peritoneal macrophages; Figure 4 It can be seen that punicalagin alone or in combination with lipopolysaccharide can upregulate the mRNA expression level of AhR in mouse peritoneal macrophages; Figure 5It can be seen that punicalagin can increase the expression level of AhR protein in THP-1 cells.

[0051] In summary, the present invention found that compared with the control group, punicalagin alone can increase the expression level of AhR in mouse peritoneal macrophages by about 5 times, and combined with LPS can increase the expression level of AhR by more than 10 times; punicalagin has a significant effect on increasing the expression of AhR protein, and as a new AhR regulator that increases the expression of AhR protein, it has extremely strong application value.

[0052] Example 2: Study on the effect of punicalagin on improving the survival rate of mice after sepsis modeling by enhancing the aryl hydrocarbon receptor

[0053] 1. Experimental materials:

[0054] 1.1 Experimental animals: SPF-grade C57BL / 6J mice, 6-8 weeks old, 18-22 g, were provided by the Experimental Animal Center of Army Medical University; AhR knockout mice and control AhR wild-type mice were bred from AhR heterozygous mice.

[0055] 1.2 Experimental reagents: Punicalagin was purchased from Chengdu Mansite Biotechnology Co., Ltd. (CAS No.: 65995-63-3, purity>98%); LPS and 2,2,2-tribromoethanol were purchased from Sigma; sterile syringes were purchased from Kangdeli Medical Device Co., Ltd.; surgical instruments were purchased from the Surgical Instrument Factory of Shanghai Medical Device Co., Ltd.

[0056] 2. Experimental methods:

[0057] 2.1. Observation of mouse survival rate

[0058] C57BL / 6J male wild-type (WT) mice and AhR knockout (AhR KO) mice were randomly divided into a model group and a model + punicalagin group. The mice in the model group were subjected to LPS and CLP modeling, and the mice in the model + punicalagin group were intraperitoneally injected with 12.5 mg / kg punicalagin PBS solution before modeling. The survival status of mice in all groups was observed every hour until 72 or 168 hours after modeling, and the mouse survival curve was drawn based on the data.

[0059] 2.2 Construction of mouse CLP model

[0060] After intraperitoneal injection of 2,2,2-tribromoethanol, mice were induced with general anesthesia. When the righting reflex of mice disappeared, the mice were fixed in supine position on the operating table. The abdomen was disinfected and skin was prepared. A midline incision was made with a length of about 1cm-2cm. The abdominal wall was cut open layer by layer to expose the cecum, which was pulled out. The contents of the cecum were gently pushed to the end of the cecum. A 3-0 silk thread was used to ligate about 1cm from the end of the cecum. A 21G needle was used to avoid blood vessels to establish a perforation model. A small amount of contents was gently squeezed out, the cecum was returned to the abdominal cavity, the abdominal wall was sutured layer by layer, and 1ml of normal saline was injected subcutaneously for fluid resuscitation. The survival time of the mice was then observed and recorded.

[0061] 2.3. Construction of mouse LPS model

[0062] The mouse endotoxin sepsis model was induced by intraperitoneal injection of LPS at a dose of 20 mg / kg. Each mouse was given 200 μl of 2 mg / ml LPS solution, i.e., 0.4 mg / mouse.

[0063] 3. Experimental results:

[0064] The results are as follows Figure 6 and Figure 7 As shown, from Figure 6 It can be seen that punicalagin improves the survival rate of wild-type mice in the LPS-induced sepsis model, but does not affect the survival rate of AhR knockout mice;

[0065] from Figure 7 It can be seen that punicalagin improves the survival rate of the CLP-induced sepsis model in wild-type mice, but does not affect the survival rate of AhR knockout mice.

[0066] In summary, punicalagin improved the survival rate of septic mice, increasing the survival rate of the LPS-induced sepsis model in wild-type mice from 20% to 40%, and increasing the survival rate of the CLP-induced sepsis model in wild-type mice from 20% to 45%.

[0067] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. These modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention, and they should all be included in the scope of the claims and specification of the present invention.

Claims

1. Application of punicalagin in the preparation of drugs for the prevention and treatment of sepsis.

2. The use according to claim 1, characterized in that: The punicalagin can regulate the expression of aryl hydrocarbon receptor.

3. The use according to claim 1 or 2, characterized in that: The sepsis includes early sepsis, severe sepsis and septic shock.

4. The use according to claim 3, characterized in that: The drug also includes pharmaceutically acceptable excipients, which include one or more of diluents, wetting agents, adhesives, disintegrants, lubricants, color and flavor regulators, solvents, solubilizers, cosolvents, emulsifiers, antioxidants, metal complexing agents, inert gases, preservatives, local analgesics, pH regulators, isotonic regulators and isotonic regulators.

5. The use according to claim 3, characterized in that: The effective dosage of the drug is 6.25-25 mg / kg.

6. The use according to claim 3, characterized in that: The dosage form of the drug includes one of injection, oral solution, pill, powder, paste, tablet, granule, powder or capsule.

7. The use according to claim 3, characterized in that: The administration route of the drug includes one of intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, oral administration, sublingual administration, nasal administration or transdermal administration.